If you thought GLP-1 medications were primarily about weight loss, the cardiovascular research is here to expand your thinking dramatically. Over the past several years, a growing body of evidence suggests that these drugs may offer significant cardiovascular benefits beyond weight loss alone. Here’s a look at what the research is showing.
The SELECT Trial: A Landmark in Cardiovascular Research
The most significant recent study in this space is the SELECT trial, published in the New England Journal of Medicine in 2023. This was a large, rigorous randomized controlled trial that enrolled over 17,000 adults with obesity or overweight and established cardiovascular disease but without type 2 diabetes.
The result was that weekly semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% compared to placebo. This was achieved in people without diabetes, meaning the benefit couldn’t be explained by blood sugar improvement alone. The drug appears to have direct cardiovascular benefits.
This finding was significant enough to influence FDA labeling and the broader policy conversation about who should have access to these medications.
How Does This Work?
Researchers are still working out the mechanisms, but several are likely at play. GLP-1 receptors are found in the heart and blood vessels. Activation of these receptors appears to reduce inflammation in the arterial walls, improve endothelial function (the health of the cells lining blood vessels), and have direct protective effects on the heart muscle.
Weight loss itself also reduces cardiovascular risk—lower blood pressure, improved cholesterol, reduced inflammation throughout the body. The cardiovascular benefit from GLP-1 medications appears to be a combination of direct drug effects and the downstream benefits of weight loss.
GLP-1 medications are not without tradeoffs. The most common side effects reported in clinical trials include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. In the SELECT trial, 16.6% of participants in the semaglutide group discontinued due to adverse events, compared with 8.2% in the placebo group. As with any medication class, the benefits should be weighed against potential risks in consultation with a healthcare provider.
Heart Failure: A New Frontier
Research is also showing promising results for GLP-1 medications in heart failure, particularly heart failure with preserved ejection fraction (HFpEF), a form of heart failure closely linked to obesity and metabolic disease that has historically been very difficult to treat.
The STEP-HFpEF trial found that semaglutide significantly improved symptoms, exercise function, and quality of life in people with HFpEF and obesity. This is a population that has had very few effective treatment options, making these results particularly meaningful.
Kidney Protection
The FLOW trial, another major study, examined semaglutide in people with type 2 diabetes and chronic kidney disease. The results showed meaningful reduction in kidney disease progression, including lower rates of kidney failure. The FDA approved semaglutide for reducing kidney disease progression in this population in early 2025, adding a new kidney-protective indication to its approved uses for adults with type 2 diabetes.
Sleep Apnea
The GLP-1 drug class is also making inroads in sleep medicine. A 2024 trial published in the New England Journal of Medicine found that tirzepatide, a related dual GIP/GLP-1 receptor agonist, significantly reduced obstructive sleep apnea (OSA) severity in people with obesity. In December 2024, the FDA approved Zepbound® (tirzepatide) as the first-ever medication for moderate-to-severe OSA in adults with obesity. Research on semaglutide specifically for OSA is ongoing, but the weight loss achieved with GLP-1 medications is known to reduce sleep apnea severity.
What Does This Mean for You?
If you’re currently on a GLP-1 medication for weight management or diabetes, the cardiovascular and organ-protective benefits represent significant added value, benefits that may not always be communicated clearly. If you have cardiovascular risk factors, kidney disease, or sleep apnea, these medications may be doing more for you than you realize.
If you’re considering starting a GLP-1 medication, the cardiovascular evidence strengthens the case beyond aesthetics and weight alone.
The Broader Implications of GLP-1 Research
GLP-1 medications are showing potential across a broader range of conditions than initially anticipated. The cardiovascular, kidney, and metabolic research is robust and continuing to grow. GLP-1 medications are proving to be far more than weight loss tools. They may play an increasingly important role in managing multiple conditions beyond metabolic health, though long-term research is ongoing.
The FDA-approved GLP-1 receptor agonist medications discussed in this article are prescription medications for specific indications: semaglutide (Ozempic®) for type 2 diabetes and to reduce cardiovascular risk in adults with type 2 diabetes and cardiovascular disease; semaglutide (Wegovy®) for chronic weight management; tirzepatide (Mounjaro®) for type 2 diabetes; and tirzepatide (Zepbound®) for chronic weight management. This article is for educational and informational purposes only and does not constitute medical advice. Individual results may vary. Consult your healthcare provider to determine if GLP-1 therapy is appropriate for your individual health situation and to discuss potential risks, side effects, and contraindications.
Leave a Comment
Your email address will not be published. Required fields are marked *